The recent discovery of the aberrant expression of DDX3Y compensating the loss of DDX3X function in tumors with c-MYC activation has opened a new area for developing new therapeutic strategies for B cell lymphomas. Here, MYC is linked to B-cell non-Hodgkin lymphoma.